Evidence map›Paper›PMID 37540330›Full record

ArticleInflammation2023

ELABELA/APJ Axis Prevents Diabetic Glomerular Endothelial Injury by Regulating AMPK/NLRP3 Pathway.

Zhida Chen, Zhe Wang, Yepeng Hu, Huangbo Lin, Li Yin, Jing Kong, Yikai Zhang, Bibi Hu, Tiekun Li, Xianan Zheng and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Inflammation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Zhida Chen *Department of Nephrology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.ORCID http://orcid.org/0000-0001-6756-0860
Zhe Wang *Department of Endocrinology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Yepeng HuDepartment of Endocrinology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Huangbo LinSchool of Medical Information Engineering, Guangzhou University of Chinese Medicine, Guangzhou, China.
Li YinDepartment of Vascular Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Jing KongDepartment of Endocrinology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Yikai ZhangDepartment of Nephrology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Bibi HuDepartment of Nephrology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Tiekun LiNanjing Kingmed Center for Clinical Laboratory, Nanjing, China.
Xianan ZhengDepartment of Endocrinology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Qiongying YangDepartment of Nephrology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Shu YeDepartment of Endocrinology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Shengyao WangDepartment of Endocrinology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Qiao ZhouDepartment of Endocrinology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Chao ZhengDepartment of Endocrinology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. chao_zheng@zju.edu.cn.ORCID http://orcid.org/0000-0002-2779-0255
Second Affiliated Hospital of Zhejiang University · CNGuangzhou University of Chinese Medicine · CNKingmed Diagnostics · CN

Funding

National Natural Science Foundation of China 82000767National Natural Science Foundation of China 82070833National Natural Science Foundation of China 82100748Natural Science Foundation of Zhejiang Province LQ22H050005Natural Science Foundation of Zhejiang Province LQ23H070003Zhejiang provincial key research & development program 2021C03070
6 · The paper itself

Abstract

ELABELA (ELA), a recently discovered peptide, is highly expressed in adult kidneys and the endothelium system. It has been identified as a novel endogenous ligand for the apelin receptor (APJ). This study aims to investigate the role of ELA in diabetic glomerular endothelial pyroptosis and its underlying mechanism. Initially, a significant decrease in ELA mRNA levels was observed in the renal cortex of db/db mice and high glucose-treated glomerular endothelial cells (GECs). It was also found that ELA deficiency in ELA

Indexed as

Diabetes MellitusDiabetic NephropathiesAMP-Activated Protein KinasesAnimalsApelin ReceptorsEndothelial CellsInflammasomesMiceNLR Family, Pyrin Domain-Containing 3 ProteinNLR ProteinsPeptide HormonesAMP-Activated Protein KinasesApela protein, mouseApelin ReceptorsAplnr protein, mouseInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinNLR ProteinsPeptide HormonesAMPKDiabetic kidney diseaseELAGlomerular endothelial injuryNLRP3

Identifiers

PMID37540330
PMCPMC10673989
OpenAlexW4385564656

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.